Exome Asset Management LLC
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 15, 2025), Exome Asset Management LLC reported 55 stock positions worth $121.3 million. Its top holding was iShares TR at 6.1% of the portfolio, followed by Bridgebio Pharma (BBIO, 5.5%) and Guardant Health (GH, 4.2%). Compared with Q1 2025, it opened 21 new positions, sold out of 15, added to 8 and reduced 17. The biggest buy was a new position in iShares TR and the biggest sale an exit from Astrazeneca PLC-Spons ADR (AZN).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0002011932
- Portfolio Value
- $121.3M (Q2 2025)
- SEC Filing
- 0001420506-25-002212 ↗ filed Aug 15, 2025
Holdings Value
Holdings 55 stocks · $121.3M
| ISHARES TR | 6.06% | 200,000 | $7.4M | New |
| BBIO Bridgebio Pharma Inc. | 5.54% | 155,533 | $6.7M | Reduce -6.0% |
| GH Guardant Health Inc. | 4.21% | 98,182 | $5.1M | Reduce -22.8% |
| GERN Geron Corp. | 3.97% | 3,414,377 | $4.8M | Add +6.2% |
| IONS Ionis Pharmaceuticals Inc. | 3.95% | 121,116 | $4.8M | Reduce -10.7% |
| THC Tenet Healthcare Corp. | 3.92% | 27,000 | $4.8M | New |
| COGT Cogent Biosciences Inc. | 3.16% | 533,647 | $3.8M | Reduce -14.2% |
| CYTK Cytokinetics Inc. | 3.16% | 115,817 | $3.8M | Add +11.9% |
| REPL Replimune Group Inc. | 3.05% | 397,846 | $3.7M | Add +34.9% |
| LLY Eli Lilly & Co. | 3.00% | 4,673 | $3.6M | No change |
| SLNO Soleno Therapeutics Inc. | 2.88% | 41,641 | $3.5M | Reduce -4.1% |
| ISRG Intuitive Surgical Inc. | 2.85% | 6,358 | $3.5M | No change |
| IRON Disc Medicine Inc. | 2.68% | 61,356 | $3.2M | Reduce -0.5% |
| NTRA Natera Inc. | 2.60% | 18,650 | $3.2M | No change |
| FULC Fulcrum Therapeutics Inc. | 2.52% | 444,949 | $3.1M | Reduce -35.4% |
| SRRK Scholar Rock Holding Corp. | 2.46% | 84,339 | $3.0M | No change |
| SNDX Syndax Pharmaceuticals Inc. | 2.38% | 308,298 | $2.9M | Reduce -8.6% |
| VSTM Verastem Inc. | 2.05% | 599,900 | $2.5M | New |
| PRAX Praxis Precision Medicines I | 2.05% | 59,002 | $2.5M | New |
| PEN Penumbra Inc. | 1.90% | 9,000 | $2.3M | No change |
| ETNB 89BIO Inc. | 1.89% | 233,426 | $2.3M | Reduce -34.0% |
| TVTX Travere Therapeutics Inc. | 1.87% | 153,278 | $2.3M | Add +29.9% |
| CNTA Centessa Pharmaceuticals Ltd. | 1.81% | 166,944 | $2.2M | Add +16.9% |
| NEKTAR THERAPEUTICS | 1.60% | 75,000 | $1.9M | New |
| WAY Waystar Holding Corp. | 1.58% | 46,900 | $1.9M | New |
| CRBP Corbus Pharmaceuticals Holdi | 1.58% | 277,317 | $1.9M | Reduce -4.3% |
| TXG 10X Genomics Inc. Class A | 1.56% | 163,658 | $1.9M | New |
| DYN Dyne Therapeutics Inc. | 1.54% | 195,933 | $1.9M | Reduce -24.2% |
| RGNX Regenxbio Inc. | 1.53% | 226,060 | $1.9M | Reduce -44.2% |
| UHS Universal Health Services-B | 1.51% | 10,100 | $1.8M | New |
| VERA Vera Therapeutics Inc. | 1.49% | 76,700 | $1.8M | New |
| CRNX Crinetics Pharmaceuticals Inc. | 1.49% | 62,700 | $1.8M | Add +22.2% |
| APLS Apellis Pharmaceuticals Inc. | 1.41% | 98,600 | $1.7M | New |
| EWTX Edgewise Therapeutics Inc. | 1.35% | 124,470 | $1.6M | Add +74.2% |
| TRAVERE THERAPEUTICS INC | 1.34% | 110,000 | $1.6M | New |
| BCRX Biocryst Pharmaceuticals Inc. | 1.28% | 172,883 | $1.5M | Add +185.3% |
| KARYOPHARM THERAPEUTICS (KPTI 3 10/15/25) | 1.26% | 2,000,000 | $1.5M | No change |
| CLDX Celldex Therapeutics Inc. | 1.22% | 73,000 | $1.5M | New |
| SAREPTA THERAPEUTICS INC (SRPT 1.25 09/15/27) | 1.19% | 2,000,000 | $1.4M | New |
| GOSS Gossamer Bio Inc. | 1.11% | 1,097,999 | $1.4M | No change |
| GPCR Structure Therapeutics Inc. | 0.92% | 53,744 | $1.1M | Reduce -47.8% |
| LEGN Legend Biotech Corp.-ADR | 0.85% | 29,100 | $1.0M | New |
| MBX MBX Biosciences Inc. | 0.59% | 63,076 | $720K | Reduce -52.6% |
| ALVO Alvotech SA | 0.59% | 78,372 | $715K | Reduce -13.0% |
| NAMS Newamsterdam Pharma Co. NV | 0.55% | 36,574 | $662K | New |
| CMPS Compass Pathways PLC | 0.49% | 213,544 | $598K | New |
| ESTA Establishment Labs Holdings | 0.46% | 13,100 | $560K | No change |
| VYNE THERAPEUTICS INC | 0.28% | 208,970 | $345K | Reduce -54.9% |
| TIL Instil Bio Inc. | 0.28% | 16,200 | $337K | New |
| ANAB Anaptysbio Inc. | 0.27% | 15,000 | $333K | Reduce -87.1% |
| ELDN Eledon Pharmaceuticals Inc. | 0.26% | 114,145 | $309K | No change |
| LQDA Liquidia Corp. | 0.21% | 20,500 | $255K | New |
| ABUS Arbutus Biopharma Corp. | 0.19% | 75,484 | $233K | New |
| ELEV Elevation Oncology Inc. | 0.03% | 110,353 | $41K | New |
| MEREO BIOPHARMA GROUP PLC | 0.03% | 14,600 | $40K | New |
Options reported separately and not counted above: AZN puts ($3.9M), AKRO puts ($3.1M), ACAD calls ($2.0M), COR calls ($1.8M), ULTRAGENYX PHARMACEUTICAL IN calls ($1.4M), UNH calls ($437K), ALTIMMUNE INC puts ($414K), FULCRUM THERAPEUTICS INC calls ($138K).
Portfolio Sells Q1 2025 → Q2 2025
| AZN Astrazeneca PLC-Spons ADR | Sold out | 0.00% | −4.23 |
| AKRO Akero Therapeutics Inc. | Sold out | 0.00% | −2.77 |
| VRDN Viridian Therapeutics Inc. | Sold out | 0.00% | −2.62 |
| SVRA Savara Inc. | Sold out | 0.00% | −2.08 |
| GEHC GE Healthcare Technology | Sold out | 0.00% | −1.84 |
| ANAB Anaptysbio Inc. | Reduce -87.1% | 0.27% | −1.67 |
| IMNM Immunome Inc. | Sold out | 0.00% | −1.59 |
| ONC Beone Medicines Ltd.-ADR | Sold out | 0.00% | −1.58 |
| RDY Dr. Reddy's Laboratories-ADR | Sold out | 0.00% | −1.39 |
| NKTR Nektar Therapeutics | Sold out | 0.00% | −1.36 |
| SNDX Syndax Pharmaceuticals Inc. | Reduce -8.6% | 2.38% | −1.33 |
| ARVN Arvinas Inc. | Sold out | 0.00% | −1.23 |
| RGNX Regenxbio Inc. | Reduce -44.2% | 1.53% | −1.07 |
| TRVI Trevi Therapeutics Inc. | Sold out | 0.00% | −0.92 |
| DYN Dyne Therapeutics Inc. | Reduce -24.2% | 1.54% | −0.88 |
| BHVN Biohaven Ltd. | Sold out | 0.00% | −0.86 |
| GPCR Structure Therapeutics Inc. | Reduce -47.8% | 0.92% | −0.68 |
| GH Guardant Health Inc. | Reduce -22.8% | 4.21% | −0.64 |
| ETNB 89BIO Inc. | Reduce -34.0% | 1.89% | −0.41 |
| VYNE THERAPEUTICS INC | Reduce -54.9% | 0.28% | −0.37 |
| AKBA Akebia Therapeutics Inc. | Sold out | 0.00% | −0.33 |
| MBX MBX Biosciences Inc. | Reduce -52.6% | 0.59% | −0.29 |
| ALVO Alvotech SA | Reduce -13.0% | 0.59% | −0.19 |
| COGT Cogent Biosciences Inc. | Reduce -14.2% | 3.16% | −0.18 |
| NUVB Nuvation Bio Inc. | Sold out | 0.00% | −0.15 |
| IRON Disc Medicine Inc. | Reduce -0.5% | 2.68% | −0.06 |
| APRE Aprea Therapeutics Inc. | Sold out | 0.00% | −0.05 |
| SLNO Soleno Therapeutics Inc. | Reduce -4.1% | 2.88% | +0.10 |
| CRBP Corbus Pharmaceuticals Holdi | Reduce -4.3% | 1.58% | +0.20 |
| IONS Ionis Pharmaceuticals Inc. | Reduce -10.7% | 3.95% | +0.28 |
| BBIO Bridgebio Pharma Inc. | Reduce -6.0% | 5.54% | +0.41 |
| FULC Fulcrum Therapeutics Inc. | Reduce -35.4% | 2.52% | +0.75 |
Portfolio Buys Q1 2025 → Q2 2025
| ISHARES TR | New | 6.06% | +6.06 |
| THC Tenet Healthcare Corp. | New | 3.92% | +3.92 |
| VSTM Verastem Inc. | New | 2.05% | +2.05 |
| PRAX Praxis Precision Medicines I | New | 2.05% | +2.05 |
| NEKTAR THERAPEUTICS | New | 1.60% | +1.60 |
| WAY Waystar Holding Corp. | New | 1.58% | +1.58 |
| TXG 10X Genomics Inc. Class A | New | 1.56% | +1.56 |
| UHS Universal Health Services-B | New | 1.51% | +1.51 |
| VERA Vera Therapeutics Inc. | New | 1.49% | +1.49 |
| APLS Apellis Pharmaceuticals Inc. | New | 1.41% | +1.41 |
| TRAVERE THERAPEUTICS INC | New | 1.34% | +1.34 |
| CLDX Celldex Therapeutics Inc. | New | 1.22% | +1.22 |
| SAREPTA THERAPEUTICS INC (SRPT 1.25 09/15/27) | New | 1.19% | +1.19 |
| BCRX Biocryst Pharmaceuticals Inc. | Add +185.3% | 1.28% | +0.87 |
| LEGN Legend Biotech Corp.-ADR | New | 0.85% | +0.85 |
| NAMS Newamsterdam Pharma Co. NV | New | 0.55% | +0.55 |
| CMPS Compass Pathways PLC | New | 0.49% | +0.49 |
| REPL Replimune Group Inc. | Add +34.9% | 3.05% | +0.47 |
| TIL Instil Bio Inc. | New | 0.28% | +0.28 |
| LQDA Liquidia Corp. | New | 0.21% | +0.21 |
| ABUS Arbutus Biopharma Corp. | New | 0.19% | +0.19 |
| ELEV Elevation Oncology Inc. | New | 0.03% | +0.03 |
| MEREO BIOPHARMA GROUP PLC | New | 0.03% | +0.03 |
| TVTX Travere Therapeutics Inc. | Add +29.9% | 1.87% | −0.02 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +16.9% | 1.81% | −0.03 |
| CRNX Crinetics Pharmaceuticals Inc. | Add +22.2% | 1.49% | −0.05 |
| EWTX Edgewise Therapeutics Inc. | Add +74.2% | 1.35% | −0.06 |
| CYTK Cytokinetics Inc. | Add +11.9% | 3.16% | −0.57 |
| GERN Geron Corp. | Add +6.2% | 3.97% | −0.61 |
Options Activity Q1 2025 → Q2 2025
| AZN Astrazeneca PLC-Spons ADR | put | New | 28,362 | $3.9M |
| AKRO Akero Therapeutics Inc. | put | New | 58,579 | $3.1M |
| ACAD Acadia Pharmaceuticals Inc. | call | New | 93,222 | $2.0M |
| COR Cencora Inc. | call | New | 6,000 | $1.8M |
| ULTRAGENYX PHARMACEUTICAL IN | call | New | 37,500 | $1.4M |
| UNH Unitedhealth Group Inc. | call | New | 1,400 | $437K |
| ALTIMMUNE INC | put | New | 107,000 | $414K |
| TRAVERE THERAPEUTICS INC | call | Sold out | 110,000 | $231Kbefore exit |
| ALDEYRA THERAPEUTICS INC | put | Sold out | 100,000 | $190Kbefore exit |
| CYTOKINETICS INC | put | Sold out | 23,000 | $141Kbefore exit |
| FULCRUM THERAPEUTICS INC | call | New | 20,000 | $138K |
| SPRINGWORKS THERAPEUTICS INC | call | Sold out | 37,500 | $129Kbefore exit |
| RHYTHM PHARMACEUTICALS INC | put | Sold out | 40,000 | $70Kbefore exit |
| GOSSAMER BIO INC | call | Sold out | 100,000 | $48Kbefore exit |
| NEKTAR THERAPEUTICS | call | Sold out | 75,000 | $23Kbefore exit |
| ROIVANT SCIENCES LTD | put | Sold out | 75,300 | $15Kbefore exit |
| VERU INC | call | Sold out | 60,000 | $900before exit |
| SOLENO THERAPEUTICS INC | put | Sold out | 11,000 | $275before exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 52 | $162.1M | GH, PRAX, TGTX, COGT, IONS |
| Q1 2026 | 45 | $169.9M | PRAX, COGT, ELVN, IONS, GH |
| Q4 2025 | 53 | $202.4M | PRAX, COGT, GH, IONS, LLY |
| Q3 2025 | 54 | $151.4M | IONS, CYTK, BBIO, COGT, GH |
| Q2 2025Amended | 55 | $121.3M | ISHARES TR, BBIO, GH, GERN, IONS |
| Q1 2025Amended | 49 | $111.6M | BBIO, GH, GERN, AZN, CYTK |
| Q4 2024 | 58 | $132.9M | BBIO, LLY, GERN, HUM, GH |
| Q3 2024Amended | 59 | $147.9M | LLY, ASND, BBIO, GPCR, TGTX |
| Q2 2024Amended | 52 | $112.3M | LLY, SRPT, ONC, TGTX, CI |
| Q1 2024 | 53 | $116.8M | LLY, RDY, ONC, CI, ALPN |